Currently, there are several tyrosine kinase inhibitors (TKIs) approved for treating CML, classified according to their potency and activity against the various mutant forms of BCR‐ABL. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.